The Genetic Effects on Vitamin D Supplementation

Sponsor
St. Mary's University, Twickenham (Other)
Overall Status
Recruiting
CT.gov ID
NCT05802433
Collaborator
(none)
67
1
3
16.7
4

Study Details

Study Description

Brief Summary

Vitamin D is essential for skeletal growth and bone health, deficiency causes rickets and osteomalacia. In the UK 29% of adults have vitamin D deficiency. It is recommended all adults take 10µg vitamin D supplement daily. Genetic variations could alter vitamin D status by affecting vitamin D metabolism. Systematic reviews found variations in VDR, GC and CYP2R1 genes are associated with vitamin D deficiency. This study aims to assess the effects between vitamin D supplementation and variations in VDR, GC and CYP2R1 genes on vitamin D status.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Vitamin D3 supplement
N/A

Detailed Description

The study design is a quantitative, randomised control trial measuring vitamin D concentrations in blood serum. All participants will be given the recommended 10µg daily dose of vitamin D supplementation. Participants will be grouped based on their genotype for each gene, as either low, medium or high-risk genotypes. The low-risk group will act as a control and the medium and high-risk groups will act as the intervention groups.

Participants will attend St Mary's University's applied science laboratory twice. During their first visit participants will provide a 2ml capillary blood sample. Blood samples are collected using lancets to prick participants' ear lobes. The serum is extracted from the blood samples, serum is stored at -80c until analysis. Participants will be given 90 10µg vitamin D supplements and instructed to take one per day for 90 days. Participants will also be instructed to not make any major changes to their habitual diet. During the second visit participants will provide 1 ml of saliva sample into the Collection Pot and a second 2ml sample of blood. Serum samples will be analysed for vitamin D concentrations using 25(OH) Vitamin D ELISA kit. DNA will be extracted from the saliva samples using PSP SalivaGene DNA Kit following the manufacturer's protocol. DNA will be genotyped for variations in the VDR, GC and CYP2R1 genes. Data will be assessed to determine if variations in these genes influenced the effectiveness of vitamin D supplementation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
67 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants are grouped based on their genetic risk of vitamin D deficiency, all participants are given 10µg vitamin D supplements for 90 daysParticipants are grouped based on their genetic risk of vitamin D deficiency, all participants are given 10µg vitamin D supplements for 90 days
Masking:
Single (Participant)
Masking Description:
Participants are not informed of their genetic variations until completion of the trial
Primary Purpose:
Basic Science
Official Title:
Effects of VDR rs7311856, GC rs2282679 and CYP2R1 rs2060793 Variants on Vitamin D Status: A Randomised Control Trial
Actual Study Start Date :
May 16, 2022
Anticipated Primary Completion Date :
Aug 25, 2023
Anticipated Study Completion Date :
Oct 5, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Control (Low risk genotype)

Participants with no genetic variation in their VDR, GC and CYP2R1 genes that would increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group is a control against the medium and high-risk intervention groups.

Dietary Supplement: Vitamin D3 supplement
10µg vitamin D3 supplement per day for 90 days

Experimental: Intervention (Medium risk genotype)

Participants with genetic variation in their VDR, GC and CYP2R1 genes that moderately increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.

Dietary Supplement: Vitamin D3 supplement
10µg vitamin D3 supplement per day for 90 days

Experimental: Intervention (High risk genotype)

Participants with genetic variation in their VDR, GC and CYP2R1 genes that increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.

Dietary Supplement: Vitamin D3 supplement
10µg vitamin D3 supplement per day for 90 days

Outcome Measures

Primary Outcome Measures

  1. vitamin D concentration [90 days]

    Effect between genetic variations and vitamin D concentration

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy adults

  • female and male

  • 18-65 years

  • completion of physical activity readiness questionnaire (PAR-Q).

Exclusion Criteria:
  • Below 18 years

  • above 65 years

  • individuals taking medications that could interact with vitamin D status

  • Individuals regularly taking daily Vitamin D supplementation during the 3 months before the intervention start date

  • major dietary changes in vitamin D intake during the intervention period

Contacts and Locations

Locations

Site City State Country Postal Code
1 St Mary's University Twickenham London Lobdon United Kingdom TW1 4SX

Sponsors and Collaborators

  • St. Mary's University, Twickenham

Investigators

  • Principal Investigator: Yiannis Mavrommatis, St. Mary's University, Twickenham

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
St. Mary's University, Twickenham
ClinicalTrials.gov Identifier:
NCT05802433
Other Study ID Numbers:
  • SMU_ETHICS_2022-23_004
First Posted:
Apr 6, 2023
Last Update Posted:
Apr 6, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2023